Update to Risk Material for Valproate- Annual Risk Acknowledgement Form

​Healthcare professionals are advised to use the March 2019 version of the Annual Risk Acknowledgement Form at the start of treatment for all girls and women of childbearing potential on valproate medicines (irrespective of indication), as part of the Pregnancy Prevention Programme.

​Please access the most up-to-date Valproate- Annual Risk Acknowledgement Form from Sanofi as they are the Marketing Authorisation Holder of Epilim:

Most up-to-date Valproate- Annual Risk Acknowledgement Form

Zentiva Pharma UK Limited no longer market this product as the licence was cancelled in March 2018.